

skeleton is esterified with 1-3 acid radicals of saturated or unsaturated carboxylic acids having an even number of 8-20 carboxylic atoms;

b) about 5-40% by weight, based on the carrier composition, of a pharmaceutically acceptable oil which is substantially pure or which is in the form of a mixture, comprising a triglyceride as essential lipophilic component; and

c) about 10-50% by weight, based on the carrier composition, of a nonionic surfactant which is substantially pure or which is in the form of a mixture, having an HLB value of more than 10, wherein said nonionic surfactant is an amphiphilic substance whose hydrophilic component consists of polyethylene oxide.

18. (new) The pharmaceutical composition of claim 17, wherein the polyethylene oxide component comprises 15 to 60 units of ethylene oxide.

19. (new) A process for the preparation of a pharmaceutical composition of claim 11, which comprises mixing components a), b), and c) and further optional pharmaceutically acceptable water-soluble excipients in any order, dispersing in this mixture the therapeutic agent which is sparingly soluble in water and, if desired, processing the dispersion to a suitable dosage form for oral administration.


20. (new) A process of claim 19, which comprises filling the dispersion into starch or hard or soft gelatin capsules.

REMARKS

The claims are 11-20. Favorable consideration of the application is requested.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080


Gabriel Lopez
Attorney for Applicant
Reg. No. 28,440
(862) 778-7882

Date: 7/21/03